ANI Pharmaceuticals Inc. recently made its U.S. launch of Diphenoxylate HCl and Atropine Sulfate Tablet to treat diarrhea.
According to IMS Health, the U.S. annual market for these drug products is around $56 million. ANI’s entrance into the market adds a third generic competitor; prior to this, just two companies marketed a generic version of the drug.
"This is the seventh product that ANI has successfully re-commercialized from its portfolio of acquired discontinued ANDA products,” ANI President and CEO Arthur Przybyl said in a statement. “Through the end of the first quarter of 2017, ANI had re-commercialized five of the 54 acquired products."
Since the launch of the first product in December 2014 through the end of the first quarter of 2017, these five products have generated cumulative net revenues of $22 million and cumulative gross profit of $12 million to ANI.
"We are pleased with the results of these launches and, while these products have been instrumental in building our base business, the opportunity to re-commercialize additional products from this acquired pipeline continues to represent a substantial growth opportunity for ANI," Przybyl said.
Alerts Sign-up